DUBLIN--(BUSINESS WIRE)--The "Global Respiratory Drugs and Devices Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The global respiratory drugs and devices market is growing at a CAGR of 7.2% during the forecast period.
Companies Mentioned
- Astrazeneca
- Adamis (Admp)
- Ads Biotechnology
- Air Liquide
- Alung Technologies
- Alvogen
- Anaxsys
- Applied Biocode Inc.
- Avita Medical
- Bayer AG
Changing lifestyle and the growing rate of obesity is considered as the prime factors affecting and driving the market. Additionally, the high frequency of people smoking, increase in urbanization along with the rising level of pollution, are also estimated to be the major factors that are contributing significantly towards the growth of the market.
However, the unfavorable scenarios in reimbursement and limited awareness and availability in emerging markets are the major factors constraints that are hindering the growth of the global respiratory drugs and devices market across the globe.
Moreover, the growing demand for remote monitoring and home care products are the key factors that are creating opportunities in the market. New product launches and collaboration in the market are likely to drive the growth of the global respiratory drugs and devices. For instance, in July 2020, Novartis AG had put forward the results from the second phase IRIDIUM study. This study result indicates that one daily treatment dose which is high and medium of enerzair; breezhaler had highlighted the improvement in the functionality of lung along with asthma.
Impact of COVID-19 on the Global Respiratory Drugs and Devices Market
The global respiratory drug and device market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation activities. However, with the lockdown restriction lifted it is likely to increase the output for respiratory drug devices for supporting the patients.
Regional Outlooks
Global respiratory drugs and devices market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is divided into North America, Europe, Asia Pacific, and Rest of the World. North America is estimated to be the leading region in the global respiratory drugs and devices market. Increasing in respiratory diseases and disorders is also one of the major factors driving the growth of the market in the region. Additionally, leading manufactures and players are present in the region along with technological advancement that are some other factors that are promoting the growth of the market.
Asia-Pacific will have Considerable Growth in the Global Respiratory Drugs and Devices Market
The Asia-Pacific region is regarded as the economies to grow and is expected to create an opportunity for market of global respiratory drugs and devices market. The rising incidence of chronic respiratory diseases such as asthma and COPD is also one of the major factors for the growth of the market in the Asia-Pacific region. Further, the market is driven by increasing urbanization along with pollution levels is another factor that is supporting the growth of the market in the region.
The Report Covers
- Market value data analysis of 2021 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global respiratory drugs and devices market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where' in the market
Key Topics Covered:
1. Current Industry Analysis and Growth Potential Outlook
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Bio-Rad Laboratories Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. CellMax Life
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Guardant Health Inc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. MDxHealth SA
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Qiagen NV
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Liquid Biopsy Market by Biomarker Type
4.1.1. Circulating Tumor Cells
4.1.2. Circulating Tumor DNA (ctDNA)
4.1.3. Others (Extracellular Vesicles)
4.2. Global Liquid Biopsy Market by Cancer Type
4.2.1. Lung Cancer
4.2.2. Breast Cancer
4.2.3. Prostate Cancer
4.2.4. Colorectal Cancer
4.2.5. Other Cancers
4.3. Global Liquid Biopsy Market by End-User
4.3.1. Hospitals and Laboratories
4.3.2. Academic and Research Centres
5. Regional Analysis
6. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/fwd543
